Phase I Study of Non-Replicating Autologous Tumor Cell Injections Using Cells Prepared With or Without GM-CSF Gene Transduction in Patients with Metastatic Renal Cell Carcinoma. Johns Hopkins Oncology Center, Baltimore, Maryland
- 1 March 1995
- journal article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 6 (3) , 347-368
- https://doi.org/10.1089/hum.1995.6.3-347
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Methods for dose finding studies in cancer clinical trials: A review and results of a monte carlo studyStatistics in Medicine, 1991
- Reversible thyroid dysfunction during treatment with GM-CSFThe Lancet, 1991
- Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapyThe Lancet, 1991
- Hypoalbuminaemia after prolonged treatment with recombinant granulocyte macrophage colony stimulating factor.BMJ, 1990
- Necrotizing Vasculitis at Granulocyte-Macrophage-Colony-Stimulating Factor Injection SitesArchives of Dermatology, 1990
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in CancerPublished by JSTOR ,1990
- Design and Analysis of Phase I Clinical TrialsPublished by JSTOR ,1989
- Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions – a phase I dose-toxicity studyBritish Journal of Cancer, 1989